OUR QUEST IS NOT TO BE BULLISH OR BEARISH, BUT TO CORRECTLY ASSESS FUTURE TRENDS

UBS rates CGF as Neutral

The Challenger board has rejected TAL Daiichi Life Australia's non-binding $11.80 per share offer as insufficient, although it remains open to negotiations.

UBS estimates a combination of regulatory capital benefits, corporate cost savings and asset management synergies could add $0.70–$1.00 per share, supporting a takeover valuation of $12.90–$13.30, representing a 30%–35% premium to the pre-bid share price.

Potential synergies include $140m in regulatory capital benefits, $15m–$30m in annual NPAT savings from corporate costs and $4m from internalising TAL's asset management, the analyst details.

However, Daiichi may not pursue Challenger's offshore reinsurance expansion through Bermuda-based Calix Re, potentially reducing FY30 EPS by -2%–3% and widening the valuation range to $12.40–$13.30.

Challenger's stronger 1Q27 update may have lifted its fundamental value by 3%–4%. No change to Neutral rating and $12.25 target price.

Citi rates INA as Buy

Citi assesses AVID Property Group's non-binding takeover proposal for Ingenia Communities, offering $5.35 per security plus a 5c distribution, totalling $5.40 in cash.

The proposal is backed by a global sovereign wealth fund and financial sponsor and requires Ingenia to terminate its planned Peet ((PPC)) acquisition.

The board granted AVID up to six weeks of soft exclusivity and ended competing bidder Warburg Pincus' data room access.

Citi now sees potential share price upside and a greater likelihood of a successful takeover.

Buy retained. Target $5.43.

Macquarie rates RMS as Upgrade to Outperform from Neutral

Following recent weakness in the share price, Macquarie upgrades Ramelius Resources to Outperform from Neutral.

Production for the September quarter of 48,800 ozs was previously reported and wet weather affected the haulage between high-grade feed sources and the process facility at Mt Magnet.

Dalgaranga was the largest feed source and recoveries beat the mine plan. The broker notes Penny is approaching the end of its life and the company will need a strong performance on costs for the rest of the financial year to achieve guidance of $2,150-2,350/oz. Target is steady at $4.20.